Company overview
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-08. TTM means trailing twelve months. Use the market date when comparing NEO with another company.
| Daily close (USD) | $16.02 |
| Market capitalization (USD) | $2,058,176,548.8 |
| Price / earnings (TTM) | Not reported |
| Price / book | 2.62 |
No matching rows. Clear the filter to see all records.
Read NEO's valuation metrics
Company size
NeoGenomics, Inc.'s recorded market capitalization is $2,058,176,548.8. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
NEO's recorded price-to-book ratio is 2.62. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research NeoGenomics, Inc. with Aurora
Use the snapshot above to ask a specific question about NEO. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow NEO's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.